Skip to main content
Top
Published in: BMC Gastroenterology 1/2009

Open Access 01-12-2009 | Research article

Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use

Authors: Sebastian Straube, Martin R Tramèr, R Andrew Moore, Sheena Derry, Henry J McQuay

Published in: BMC Gastroenterology | Issue 1/2009

Login to get access

Abstract

Background

Some people who suffer an upper gastrointestinal bleed or perforation die. The mortality rate was estimated at 12% in studies published before 1997, but a systematic survey of more recent data is needed. Better treatment is likely to have reduced mortality. An estimate of mortality is helpful in explaining to patients the risks of therapy, especially with NSAIDs.

Methods

A systematic review of studies published before 1997, and between 1997 and 2008. Any study architecture was acceptable if it reported on cases who died from any cause of upper gastrointestinal bleed or perforation. Analyses were conducted separately for all cases, and those prescribed NSAID or aspirin.

Results

Information was available for 61,067 cases (81% published since 1997) of whom 5,001 died. The mortality rate in all cases fell significantly, from 11.6% (95% confidence interval, 11.0 to 12.2) in pre-1997 studies to 7.4% (7.2 to 7.6) in those published since 1997. In 5,526 patients taking NSAID or aspirin, mortality increased, from 14.7% (13.6 to 15.8) before 1997 to 20.9% (18.8 to 22.9) since 1997.

Conclusion

Upper gastrointestinal bleed or perforation still carries a finite risk of death. Differences in study architecture, population characteristics, risk factors, definition of mortality, and reporting of outcomes impose limitations on interpreting effect size. Data published since 1997 suggest that mortality in patients suffering from an upper gastrointestinal bleed or perforation has fallen to 1 in 13 overall, but remains higher at about 1 in 5 in those exposed to NSAID or aspirin.
Appendix
Available only for authorised users
Literature
1.
go back to reference Tramèr MR, Moore RA, Reynolds DJ, McQuay HJ: Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain. 2000, 85: 169-182. 10.1016/S0304-3959(99)00267-5.CrossRefPubMed Tramèr MR, Moore RA, Reynolds DJ, McQuay HJ: Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain. 2000, 85: 169-182. 10.1016/S0304-3959(99)00267-5.CrossRefPubMed
2.
go back to reference Lim CH, Vani D, Shah SG, Everett SM, Rembacken BJ: The outcome of suspected upper gastrointestinal bleeding with 24-hour access to upper gastrointestinal endoscopy: a prospective cohort study. Endoscopy. 2006, 38: 581-585. 10.1055/s-2006-925313.CrossRefPubMed Lim CH, Vani D, Shah SG, Everett SM, Rembacken BJ: The outcome of suspected upper gastrointestinal bleeding with 24-hour access to upper gastrointestinal endoscopy: a prospective cohort study. Endoscopy. 2006, 38: 581-585. 10.1055/s-2006-925313.CrossRefPubMed
3.
go back to reference Kolkman JJ, Meuwissen SG: A review on treatment of bleeding peptic ulcer: a collaborative task of gastroenterologist and surgeon. Scand J Gastroenterol Suppl. 1996, 218: 16-25. 10.3109/00365529609094726.CrossRefPubMed Kolkman JJ, Meuwissen SG: A review on treatment of bleeding peptic ulcer: a collaborative task of gastroenterologist and surgeon. Scand J Gastroenterol Suppl. 1996, 218: 16-25. 10.3109/00365529609094726.CrossRefPubMed
4.
go back to reference Lanas A, Perez-Aisa MA, Feu F, Ponce J, Saperas E, Santolaria S, Rodrigo L, Balanzo J, Bajador E, Almela P, Navarro JM, Carballo F, Castro M, Quintero E, Investigators of the Asociación Española de Gastroenterología (AEG): A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol. 2005, 100: 1685-1693. 10.1111/j.1572-0241.2005.41833.x.CrossRefPubMed Lanas A, Perez-Aisa MA, Feu F, Ponce J, Saperas E, Santolaria S, Rodrigo L, Balanzo J, Bajador E, Almela P, Navarro JM, Carballo F, Castro M, Quintero E, Investigators of the Asociación Española de Gastroenterología (AEG): A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol. 2005, 100: 1685-1693. 10.1111/j.1572-0241.2005.41833.x.CrossRefPubMed
5.
go back to reference Richardson CG, Chalmers A, Llewellyn-Thomas HA, Klinkhoff A, Carswell A, Kopec JA: Pain relief in osteoarthritis: patients' willingness to risk medication-induced gastrointestinal, cardiovascular, and cerebrovascular complications. J Rheumatol. 2007, 34: 1569-1575.PubMed Richardson CG, Chalmers A, Llewellyn-Thomas HA, Klinkhoff A, Carswell A, Kopec JA: Pain relief in osteoarthritis: patients' willingness to risk medication-induced gastrointestinal, cardiovascular, and cerebrovascular complications. J Rheumatol. 2007, 34: 1569-1575.PubMed
6.
go back to reference Moore RA, Derry S, McQuay HJ, Paling J: What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs. Arthritis Res Ther. 2008, 10: R20-10.1186/ar2373.CrossRefPubMedPubMedCentral Moore RA, Derry S, McQuay HJ, Paling J: What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs. Arthritis Res Ther. 2008, 10: R20-10.1186/ar2373.CrossRefPubMedPubMedCentral
7.
go back to reference Tan SB, Goh C, Thumboo J, Che W, Chowbay B, Cheung YB: Risk perception is affected by modes of risk presentations among Singaporeans. Ann Acad Med Singapore. 2005, 34: 184-187.PubMed Tan SB, Goh C, Thumboo J, Che W, Chowbay B, Cheung YB: Risk perception is affected by modes of risk presentations among Singaporeans. Ann Acad Med Singapore. 2005, 34: 184-187.PubMed
8.
go back to reference Babaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS: Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2005, 294: 448-454. 10.1001/jama.294.4.448.CrossRefPubMed Babaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS: Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2005, 294: 448-454. 10.1001/jama.294.4.448.CrossRefPubMed
9.
go back to reference Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Seward JB, Bailey KR, Iwasaka T, Tsang TS: Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study. Stroke. 2005, 36: 2362-2366. 10.1161/01.STR.0000185927.63746.23.CrossRefPubMed Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Seward JB, Bailey KR, Iwasaka T, Tsang TS: Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study. Stroke. 2005, 36: 2362-2366. 10.1161/01.STR.0000185927.63746.23.CrossRefPubMed
10.
go back to reference Murphy MJ, Wei L, Watson AD, MacDonald TM: 'Real-life' reduction in cholesterol with statins, 1993 to 2002. Br J Clin Pharmacol. 2008, 65: 587-592. 10.1111/j.1365-2125.2007.03066.x.CrossRefPubMedPubMedCentral Murphy MJ, Wei L, Watson AD, MacDonald TM: 'Real-life' reduction in cholesterol with statins, 1993 to 2002. Br J Clin Pharmacol. 2008, 65: 587-592. 10.1111/j.1365-2125.2007.03066.x.CrossRefPubMedPubMedCentral
11.
go back to reference Moore RA, Derry S, Phillips CJ, McQuay HJ: Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord. 2006, 7: 79-10.1186/1471-2474-7-79.CrossRefPubMedPubMedCentral Moore RA, Derry S, Phillips CJ, McQuay HJ: Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord. 2006, 7: 79-10.1186/1471-2474-7-79.CrossRefPubMedPubMedCentral
12.
go back to reference Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet. 1999, 354: 1896-1900. 10.1016/S0140-6736(99)04149-5.CrossRefPubMed Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet. 1999, 354: 1896-1900. 10.1016/S0140-6736(99)04149-5.CrossRefPubMed
13.
go back to reference Lemeshow AR, Blum RE, Berlin JA, Stoto MA, Colditz GA: Searching one or two databases was insufficient for meta-analysis of observational studies. J Clin Epidemiol. 2005, 58: 867-873. 10.1016/j.jclinepi.2005.03.004.CrossRefPubMed Lemeshow AR, Blum RE, Berlin JA, Stoto MA, Colditz GA: Searching one or two databases was insufficient for meta-analysis of observational studies. J Clin Epidemiol. 2005, 58: 867-873. 10.1016/j.jclinepi.2005.03.004.CrossRefPubMed
14.
go back to reference Ruppen W, Derry S, McQuay H, Moore RA: Incidence of epidural hematoma, infection, and neurologic injury in obstetric patients with epidural analgesia/anesthesia. Anesthesiology. 2006, 105: 394-399. 10.1097/00000542-200608000-00023.CrossRefPubMed Ruppen W, Derry S, McQuay H, Moore RA: Incidence of epidural hematoma, infection, and neurologic injury in obstetric patients with epidural analgesia/anesthesia. Anesthesiology. 2006, 105: 394-399. 10.1097/00000542-200608000-00023.CrossRefPubMed
15.
go back to reference Tahir SM, Price LL, Shah PB, Welt FG: Eighteen year (1985–2002) analysis of incidence, mortality, and cardiac procedure outcomes of acute myocardial infarction in patients ≥ 65 years of age. Am J Cardiol. 2008, 101: 930-936. 10.1016/j.amjcard.2007.11.040.CrossRefPubMed Tahir SM, Price LL, Shah PB, Welt FG: Eighteen year (1985–2002) analysis of incidence, mortality, and cardiac procedure outcomes of acute myocardial infarction in patients ≥ 65 years of age. Am J Cardiol. 2008, 101: 930-936. 10.1016/j.amjcard.2007.11.040.CrossRefPubMed
16.
go back to reference Hernández-Díaz S, Rodríguez LA: Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000, 160: 2093-2099. 10.1001/archinte.160.14.2093.CrossRefPubMed Hernández-Díaz S, Rodríguez LA: Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000, 160: 2093-2099. 10.1001/archinte.160.14.2093.CrossRefPubMed
17.
go back to reference Garcia Rodríguez LA, Hernández-Díaz S: The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res. 2001, 3: 98-101. 10.1186/ar146.CrossRefPubMed Garcia Rodríguez LA, Hernández-Díaz S: The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res. 2001, 3: 98-101. 10.1186/ar146.CrossRefPubMed
18.
go back to reference Shuster JJ: Fixing the number of events in large comparative trials with low event rates: a binomial approach. Controlled Clinical Trials. 1993, 14: 198-208. 10.1016/0197-2456(93)90003-V.CrossRefPubMed Shuster JJ: Fixing the number of events in large comparative trials with low event rates: a binomial approach. Controlled Clinical Trials. 1993, 14: 198-208. 10.1016/0197-2456(93)90003-V.CrossRefPubMed
19.
go back to reference Flather MD, Farkouh ME, Pogue JM, Yusuf S: Strengths and limitations of meta-analysis: larger studies may be more reliable. Control ClinTrials. 1977, 18: 568-579. 10.1016/S0197-2456(97)00024-X.CrossRef Flather MD, Farkouh ME, Pogue JM, Yusuf S: Strengths and limitations of meta-analysis: larger studies may be more reliable. Control ClinTrials. 1977, 18: 568-579. 10.1016/S0197-2456(97)00024-X.CrossRef
20.
go back to reference Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ: Size is everything–large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain. 1998, 78: 209-216. 10.1016/S0304-3959(98)00140-7.CrossRefPubMed Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ: Size is everything–large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain. 1998, 78: 209-216. 10.1016/S0304-3959(98)00140-7.CrossRefPubMed
Metadata
Title
Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use
Authors
Sebastian Straube
Martin R Tramèr
R Andrew Moore
Sheena Derry
Henry J McQuay
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2009
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-9-41

Other articles of this Issue 1/2009

BMC Gastroenterology 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine